Salivary gland acinar cell carcinoma: Long-term treatment experience

Malignant tumors of the salivary glands are a rare type of neoplasm in the head and neck region. Adenoid cystic carcinoma of the salivary gland is characterized by a high propensity for perineural invasion and frequent local and distant recurrences. The primary treatment for localized adenoid cystic carcinoma of the salivary gland is surgical removal of the tumor, while radiation therapy is considered the most effective for local recurrences. However, modern treatment methods for recurrent or metastatic adenoid cystic carcinoma of the salivary gland do not always yield the expected results. The disease is rare, which has led to limited understanding of its etiopathogenesis; however, several genetic mutations and biomarkers associated with the onset and/or progression of adenoid cystic carcinoma of the salivary gland have been identified. The discovery of these mutations has made targeted precision therapy possible, with ongoing research and development in this area. This article presents a case history of long-term (25 years) observation and successful treatment of adenoid cystic carcinoma of the salivary gland, which was accompanied by multiple progressions and adjustments in systemic therapy based on the genetic characteristics of the tumor. The aim of this publication is not only to present a rare clinical observation but also to highlight current issues, modern approaches, and emerging trends in the diagnosis and treatment of adenoid cystic carcinoma of the salivary gland.

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. https://doi.org/10.3322/caac.21834.

2. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). М.: МНИОИ; 2024. 276 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2024/08/zis-2023-elektronnaya-versiya.pdf.

3. Castelnuovo P, Turri-Zanoni M. Adenoid Cystic Carcinoma. Adv Otorhinolaryngol. 2020;84:197–209. https://doi.org/10.1159/000457939.

4. Saleh E, Ukwas A. Adenoid Cystic Carcinoma of Salivary Glands: A Ten-Year Review and an Assessment of the Current Management, Surgery, Radiotherapy, and Chemotherapy. Int J Otolaryngol. 2023:7401458. https://doi.org/10.1155/2023/7401458.

5. Gao T, Shen Z, Ma C, Li Y, Kang X, Sun M. The CCL5/CCR5 Chemotactic Pathway Promotes Perineural Invasion in Salivary Adenoid Cystic Carcinoma. J Oral Maxillofac Surg. 2018;76(8):1708–1718. https://doi.org/10.1016/j.joms.2018.02.009.

6. Bolotina LV, Vladimirova LYu, Dengina NV, Kutukova SI, Novik AV, Romanov IS. Tumors of the head and neck. Malignant Tumours. 2024;14(3s2-1):160–182. (In Russ.) https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-09.

7. Colevas AD, Cmelak AJ, Pfister DG, Spencer S, Adkins D, Birkeland AC et al. NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025;23(2):2–11. https://doi.org/10.6004/jnccn.2025.0007.

8. Ishida E, Ogawa T, Rokugo M, Ishikawa T, Wakamori S, Ohkoshi A et al. Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up. Head Face Med. 2020;16(1):14. https://doi.org/10.1186/s13005-020-00226-2.

9. Ali S, Palmer FL, Katabi N, Lee N, Shah JP, Patel SG, Ganly I. Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope. 2017;127(10):2265–2269. https://doi.org/10.1002/lary.26565.

10. Saprina OA, Kropotov MA, Tulyandin SA, Ganina KA, Kozlov NA, Vizigina BB. Current trends in the treatment of recurrent adenocystic cancer of the salivary glands: case report. Head and Neck Tumors. 2022;12(4):109–115. (In Russ.) https://doi.org/10.17650/2222-1468-2022-12-4-109-115.

11. Locati LD, Cavalieri S, Bergamini C, Resteghini C, Colombo E, Calareso G et al. Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. J Clin Oncol. 2021;39(36):4061–4068. https://doi.org/10.1200/JCO.21.00468.

12. Filippov IA, Shvedsky MS, Gaisina EA, Bakhova LA. Positive results of treatment of adenocystic carcinoma of the parotid salivary gland with lenvatinib. Head and Neck Tumors. 2024;14(3):10–13. (In Russ.) https://doi.org/10.17650/2222-1468-2024-14-3-10-13.

13. Liu H, Chen L, Wang C, Zhou H. The expression and significance of vascular endothelial growth factor A in adenoid cystic carcinoma of palatal salivary gland. Eur Arch Otorhinolaryngol. 2022;279(12):5869–5875. https://doi.org/10.1007/s00405-022-07502-8.

14. Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18. https://doi.org/10.1186/2045-824X-6-18.

15. Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103. https://doi.org/10.1016/j.canlet.2013.07.007.

16. Moriyama E, Nagasu S, Tanaka T, Shimotsuura Y, Ono T, Umeno H et al. Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer. Front Oncol. 2023;13:1247435. https://doi.org/10.3389/fonc.2023.1247435.

17. Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020;31(3):412–421. https://doi.org/10.1016/j.annonc.2019.11.018.

18. Cohen RB, Delord JP, D o i T, Piha-Paul SA, Liu SV, Gilbert J et al. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. Am J Clin Oncol. 2018;41(11):1083–1088. https://doi.org/10.1097/COC.0000000000000429.

19. Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N et al. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2019;37(18):1529–1537. https://doi.org/10.1200/JCO.18.01859.

20. Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer. 2020;126(9):1888–1894. https://doi.org/10.1002/cncr.32754.